Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artelo Biosciences, Inc. (NASDAQ: ARTL) SEC filings page on Stock Titan provides structured access to the company’s U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on lipid-signaling pathways and the endocannabinoid system, Artelo uses its SEC filings to report on clinical development, capital formation, governance changes, and listing status.
Here you can review Form 10-K annual reports and Form 10-Q quarterly reports (when filed) for detailed discussions of Artelo’s pipeline, including programs such as ART27.13 for cancer anorexia-cachexia syndrome, ART26.12 as a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, and ART12.11, its CBD-TMP cocrystal composition. These reports typically describe risk factors, research and development priorities, intellectual property, and liquidity and capital resources.
Form 8-K current reports are particularly important for ARTL, as they capture material events such as underwritten public offerings, private placements of convertible notes and warrants, cooperation agreements with shareholders, amendments to bylaws and articles of incorporation, executive appointments, and Nasdaq listing notifications. For example, an 8-K dated November 25, 2025 discloses a Nasdaq delist determination letter related to stockholders’ equity requirements and the company’s intention to appeal.
Investors can also use this page to access registration statements such as Form S-1 and Form S-3, which describe the terms of securities offerings, resale registrations for warrants and convertible notes, and related risk disclosures. Where available, Section 16 filings (Forms 3, 4, and 5) provide insight into insider ownership and transactions involving directors and officers.
Stock Titan’s platform enhances these filings with AI-generated summaries that highlight key terms, financial and capital structure changes, and program-related disclosures, helping users quickly understand how each document relates to Artelo’s clinical pipeline, governance, and Nasdaq listing status.
Artelo Biosciences' prospectus supplement describes terms for issuing debt securities, warrants and units and the broad rights, remedies and amendment limits under the indenture. It discloses that the company currently receives UK R&D tax credits for clinical trials but expects such credits to be unavailable for expenditures outside the UK with effect from April 2024. The filing states the company will need additional financing to pursue its business objectives and acknowledges failure to obtain financing could materially impair operations. Detailed provisions cover designation, pricing, interest, currency, redemption, default events and amendment/consent thresholds for any series of securities.
Artelo Biosciences (ARTL) disclosure describes terms for offering debt securities, warrants and units under an indenture, including extensive customizable features such as interest rates, denominations, currencies, security, covenants, events of default and amendment limitations. The filing states the company needs additional financing and warns operations could be adversely affected if such financing is unavailable. It notes the company currently receives UK R&D tax credits for clinical trials but those credits are not expected to apply to expenditures outside the UK starting April 2024. The supplement also summarizes trustee remedies, defeasance mechanics, and procedural rights for holders relating to defaults and amendments.
Artelo Biosciences is updating its at-the-market offering to cover up to
This reduces the prior at-the-market capacity from
The company also notes a public float of
Artelo Biosciences, Inc. reported interim Phase 2 results from its Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 for cancer anorexia-cachexia syndrome (CACS), a condition that affects up to
Artelo Biosciences, Inc. reported the results of a Special Meeting of Stockholders held on August 28, 2025. There were 704,425 shares of common stock outstanding as of the July 25, 2025 record date, and 365,886 shares were represented at the meeting, either in person or by proxy.
Stockholders voted on three matters. One matter received 325,388 votes for, 38,731 against and 1,767 abstentions. A second matter received 63,903 votes for, 130,740 against, 782 abstentions and 170,461 broker non-votes. A third matter received 338,395 votes for, 21,362 against and 6,129 abstentions. The filing lists only the vote totals, not the text of each proposal.
Artelo Biosciences reports terminating a previously agreed private placement and a related consulting arrangement. The company and accredited investors signed a Termination and Mutual Release Agreement on August 19, 2025 that voids from inception a Securities Purchase Agreement covering 593,252 common shares and warrants to purchase up to 2,126,809 shares, along with all related documents. Artelo must return any purchase price previously received and has paid
Separately, Artelo and ABK Labs, Inc. agreed to terminate a Consulting Agreement and a Consultant Warrant for up to 55,000 shares, effective August 16, 2025. The consultant irrevocably forfeited all vesting and exercise rights under the warrant, and both sides exchanged broad mutual releases of claims, with no cash consideration paid in connection with this termination.
Artelo Biosciences filed a Form D reporting a Regulation D exempt offering under Rule 506(b) for a total offering of $9,475,000, all of which has been sold with $0 remaining. The filing identifies the securities as equity, options/warrants and securities to be acquired upon exercise, and lists the first sale date as 2025-08-05. The issuer indicates the offering will not last more than one year.
The notice records 18 investors, states $0 in sales commissions and finders' fees, and reports
Artelo Biosciences reported a quarterly net loss of $3.221 million and a six-month net loss of $5.593 million, while holding $2.066 million in cash and cash equivalents as of June 30, 2025. Current liabilities increased to $5.712 million, producing a working capital deficit of $3.479 million, and management discloses substantial doubt about the Company’s ability to continue as a going concern within one year.
The company completed financings including $900,000 of convertible notes bearing 12% interest (net carrying value $791,000), a June private placement that generated $1.425 million gross ($1.079 million net), an ATM sales agreement for up to $6.5 million, and an expected August PIPE targeting approximately $9.475 million. The Company adopted a Digital Asset Treasury strategy to acquire Solana (SOL); under ASU 2023-08 SOL fair-value changes will flow through net income.